can1012
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2021 (NCT04987112)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Toll-like receptor 7AGONIST
TLR7 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06410703 | Phase 1/Phase 2 (Phase 2) | Jun 27, 2024 | Canwell Biotech Limited |
| NCT05580991 | Phase 1 | Sep 9, 2022 | Canwell Biotech Limited |
| NCT04987112 | Phase 1 | Sep 1, 2021 | CanWell Pharma Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canwell Biotech Limited | For profit | 2 | 2 | 2 | 2022 |
| CanWell Pharma Inc. | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1